留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HBP、IL-18联合IL-6对脓毒症病情严重程度及预后的预测价值

汤亚杰 王湛元 宋黎洁 陆国玉 刘成 陶言言

汤亚杰, 王湛元, 宋黎洁, 陆国玉, 刘成, 陶言言. HBP、IL-18联合IL-6对脓毒症病情严重程度及预后的预测价值[J]. 中华全科医学, 2025, 23(7): 1115-1118. doi: 10.16766/j.cnki.issn.1674-4152.004077
引用本文: 汤亚杰, 王湛元, 宋黎洁, 陆国玉, 刘成, 陶言言. HBP、IL-18联合IL-6对脓毒症病情严重程度及预后的预测价值[J]. 中华全科医学, 2025, 23(7): 1115-1118. doi: 10.16766/j.cnki.issn.1674-4152.004077
TANG Yajie, WANG Zhanyuan, SONG Lijie, LU Guoyu, LIU Cheng, TAO Yanyan. Predictive value of HBP, IL-18 combined with IL-6 for disease severity and prognosis in sepsis[J]. Chinese Journal of General Practice, 2025, 23(7): 1115-1118. doi: 10.16766/j.cnki.issn.1674-4152.004077
Citation: TANG Yajie, WANG Zhanyuan, SONG Lijie, LU Guoyu, LIU Cheng, TAO Yanyan. Predictive value of HBP, IL-18 combined with IL-6 for disease severity and prognosis in sepsis[J]. Chinese Journal of General Practice, 2025, 23(7): 1115-1118. doi: 10.16766/j.cnki.issn.1674-4152.004077

HBP、IL-18联合IL-6对脓毒症病情严重程度及预后的预测价值

doi: 10.16766/j.cnki.issn.1674-4152.004077
基金项目: 

安徽省高校自然科学研究重点项目 2023AH051996

蚌埠医学院自然科学重点项目 2021byzd157

蚌埠医学院科技项目自然科学类重点项目 2022byzd039

详细信息
    通讯作者:

    陶言言,E-mail: taoyanyan1981@163.com

  • 中图分类号: R631

Predictive value of HBP, IL-18 combined with IL-6 for disease severity and prognosis in sepsis

  • 摘要:   目的   脓毒症病死率高,发展迅速,为评估脓毒症患者的预后及病情分级,本研究通过分析肝素结合蛋白(HBP)、白介素-6(IL-6)及白介素-18(IL-18)的表达水平,探讨这些指标对脓毒症患者的预测价值。   方法   选取2023年1月—2024年6月蚌埠医科大学第一附属医院急诊医学科和ICU收治的80例患者。根据脓毒症诊断标准,将患者分为非脓毒症组即普通感染组20例、脓毒症组35例、脓毒症休克组25例;比较3组患者HBP、IL-18、IL-6水平;以28 d为研究终点,将脓毒症患者分为生存组和死亡组,比较2组HBP、IL-18、IL-6水平;采用Pearson分析研究HBP、IL-18、IL-6与急性生理与慢性健康状况Ⅱ评分(APACHE-Ⅱ评分)、序贯器官衰竭评分(SOFA评分)的相关性;采用ROC曲线分析HBP、IL-6、IL-18对脓毒症患者预后的评估价值。   结果   普通感染组、脓毒症组的HBP、IL-6、IL-18明显低于脓毒症休克组,差异有统计学意义(P < 0.001);死亡组的HBP、IL-6、IL-18明显高于存活组,差异有统计学意义(P < 0.001)。HBP、IL-6、IL-18与SOFA评分和APACHE-Ⅱ评分呈正相关关系。HBP、IL-6、IL-18单独预测脓毒症患者预后的ROC曲线下面积分别为0.769、0.793、0.818,约登指数分别为0.460、0.491、0.553,3项指标联合预测脓毒症患者预后的ROC曲线下面积为0.842,约登指数为0.587,3项指标联合的预测价值更高。   结论   HBP、IL-6、IL-18血清水平可有效反映脓毒症患者的病情严重程度,且3种炎症因子联合检测时对脓毒症患者的预后比各指标单独检测的评估效能更高。

     

  • 图  1  3种炎症因子单独及联合预测脓毒症患者预后的ROC曲线

    Figure  1.  ROC curves for predicting the prognosis of sepsis patients using three inflammatory factors individually and in combination

    表  1  普通感染组、脓毒症组和脓毒症休克组患者一般资料比较

    Table  1.   General infection group, sepsis group, and septic shock group

    项目 普通感染组(n=20) 脓毒症组(n=35) 脓毒症休克组(n=25) 统计量 P
    性别(男性/女性,例) 10/10 22/13 16/9 1.111a 0.292
    年龄(x±s,岁) 69.60±14.75 68.68±13.65 67.76±8.27 0.120b 0.886
    BMI(x±s) 24.52±2.49 23.74±2.13 23.67±2.85 0.816b 0.445
    基础疾病[例(%)]
      高血压 10(50.00) 13(37.14) 12(48.00) 1.122a 0.571
      糖尿病 7(35.00) 10(28.57) 8(32.00) 0.254a 0.881
      冠心病 5(25.00) 15(42.86) 9(36.00) 1.757a 0.415
      脑梗死 6(30.00) 7(20.00) 4(16.00) 1.359a 0.507
    感染部位[例(%)] 0.435a 0.427
      呼吸系统 9(45.00) 20(57.14) 8(32.00)
      泌尿系统 4(20.00) 5(14.29) 6(24.00)
      消化系统 7(35.00) 10(28.57) 11(44.00)
    WBC[M(P25, P75),×109/L] 7.49(5.65, 12.57) 12.75(8.46, 15.25) 8.57(5.59, 18.37) 5.741c 0.057
    CRP[M(P25, P75),mg/L] 75.42(56.85, 108.89) 117.80(65.51, 170.13) 119.32(61.25, 166.85) 4.326c 0.105
    SCr(x±s,μmol/L) 101.09±25.22 94.72±17.24 103.71±19.47 0.371b 0.690
    注:a为χ2值,bF值,cH值。
    下载: 导出CSV

    表  2  普通感染组、脓毒症组和脓毒症休克组HBP、IL-6、IL-18水平及APACHE-Ⅱ评分、SOFA评分比较(x ±s)

    Table  2.   HBP, IL-6, IL-18, APACHE Ⅱ score, and SOFA score in the general infection, sepsis, and septic shock group (x ±s)

    组别 例数 HBP(ng/mL) IL-6(pg/mL) IL-18(pg/mL) APACHE-Ⅱ评分(分) SOFA评分(分)
    普通感染组 20 37.25±1.37 44.75±2.55 87.30±5.19
    脓毒症组 35 69.74±4.80a 60.25±3.95a 106.31±12.75a 15.02±2.91 7.51±1.90
    脓毒症休克组 25 80.40±5.74ab 90.48±8.54ab 133.80±14.63ab 23.12±4.85 15.88±2.31
    统计量 528.087c 402.232c 85.857c 8.045d 15.345d
    P < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
    注:与普通感染组比较,aP < 0.001;与脓毒症组比较,bP < 0.001。cF值,dt值。
    下载: 导出CSV

    表  3  HBP、IL-6、IL-18与APACHE-Ⅱ评分、SOFA评分的相关性分析

    Table  3.   Correlation analysis of HBP, IL-6, and IL-18 with APACHE Ⅱ and SOFA scores

    指标 APACHE Ⅱ评分 SOFA评分
    r P r P
    IL-6 0.707 < 0.001 0.868 < 0.001
    HBP 0.588 < 0.001 0.679 < 0.001
    IL-18 0.735 < 0.001 0.759 < 0.001
    下载: 导出CSV

    表  4  不同预后脓毒症患者HBP、IL-6、IL-18水平和APACHE-Ⅱ评分、SOFA评分比较

    Table  4.   Comparison of HBP, IL-6, IL-18 levels, APACHE Ⅱ scores, and SOFA scores in sepsis patients with different prognoses

    组别 例数 HBP
    (x±s, pg/mL)
    IL-6
    (x±s, pg/mL)
    IL-18
    (x±s, pg/mL)
    APACHE-Ⅱ评分
    (x±s, 分)
    SOFA评分
    [M(P25, P75), 分]
    生存组 46 72.63±7.06 69.52±13.85 112.82±17.93 16.93±4.95 10.16(6.62,13.77)
    死亡组 14 79.28±6.26 84.85±17.54 134.01±13.57 23.57±5.24 12.77(9.73, 16.95)
    统计量 3.162a 3.403a 4.066a 4.339a -2.027b
    P < 0.001 < 0.001 < 0.001 < 0.001 < 0.043
    注:at值,bZ值。
    下载: 导出CSV

    表  5  HBP、IL-6、IL-18对脓毒症患者预后的预测效能

    Table  5.   Predictive efficacy of HBP, IL-6, and IL-18 for sepsis prognosis

    项目 AUC 95% CI P 截断值 约登
    指数
    灵敏度
    (%)
    特异度
    (%)
    HBP 0.769 0.640~0.898 < 0.001 74.5 0.460 78.6 67.4
    IL-6 0.793 0.661~0.924 < 0.001 87.0 0.491 85.7 69.6
    IL-18 0.818 0.711~0.920 < 0.001 121.5 0.553 64.3 84.8
    三者联合 0.842 0.741~0.942 < 0.001 0.587 92.9 65.2
    下载: 导出CSV
  • [1] ZHANG Y Y, NING B T. Signaling pathways and intervention therapies in sepsis[J]. Signal Transduct Target Ther, 2021, 6(1): 407. DOI: 10.1038/s41392-021-00816-9.
    [2] SUN B S, LEI M X, ZHANG J Q, et al. Acute lung injury caused by sepsis: how does it happen?[J]. Front Med (Lausanne), 2023, 10: 1289194. DOI10.3389/fmed. 2023.1289194.
    [3] BARICHELLO T, GENEROSO J S, SINGER M, et al. Biomarkers for sepsis: more than just fever and leukocytosis: a narrative review[J]. Crit Care, 2022, 26(1): 14. DOI: 10.1186/s13054-021-03862-5.
    [4] CONG S, MA T G, DI X, et al. Diagnostic value of neutrophil CD64, procalcitonin, and interleukin-6 in sepsis: a meta-analysis[J]. BMC Infect, 2021, 21(1): 384. DOI: 10.1186/s12879-021-06064-0.
    [5] OTHMAN A, SEKHERI M, FILEP J G. Roles of neutrophil granule proteins in orchestrating inflammation and immunity[J]. FEBS J, 2022, 289(14): 3932-3953. doi: 10.1111/febs.15803
    [6] 冯立伟, 王婕莹, 王洪亮, 等. 肝素结合蛋白在重症患者中的临床应用[J]. 中国急救医学, 2023, 43(7): 579-584.

    FENG L W, WANG J Y, WANG H L, et al. Clinical application of heparin-binding protein in severe patients[J]. Chinese Journal of Critical Care Medicine, 2023, 43(7): 579-584.
    [7] 李璐, 李文强, 胡念丹, 等. 血清IL-18水平评估脓毒症患者病情严重程度的价值[J]. 中国急救复苏与灾害医学杂志, 2022, 17(2): 221-224, 229.

    LI L, LI W Q, HU N D, et al. The value of serum IL-18 level in evaluating the severity of sepsis[J]. China Journal of Emergency Resuscitation and Disaster Medicine, 2022, 17(2): 221-224, 229.
    [8] EVANS L, RHODES A, ALHAZZANI W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med, 2021, 49(11): 1181-1247.
    [9] PIERRAKOS C, VELISSARIS D, BISDORFF M, et al. Biomarkers of sepsis: time for a reappraisal[J]. Crit Care, 2020, 24(1): 287. DOI: 10.1186/s13054-020-02993-5.
    [10] IHIM S A, ABUBAKAR S D, ZIAN Z, et al. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment[J]. Front Immunol, 2022, 13: 919973. DOI: 10.3389/fimmu.2022.919973.
    [11] 曹轮飞, 程亚辉, 赵振东. 脓毒症患者血清PCT和IL-10及IL-18水平及其预后价值分析[J]. 医药论坛杂志, 2023, 44(16): 35-39.

    CAO L F, CHENG Y H, ZHAO Z D, et al. Analysis of serum levels of PCT, IL-10, and IL-18 and their prognostic values in patients with sepsis[J]. Journal of Medical Forum, 2023, 44(16): 35-39.
    [12] WU Y L, YO C H, HSU W T, et al. Accuracy of heparin-binding protein in diagnosing sepsis: a systematic review and meta-analysis[J]. Crit Care Med, 2021, 49(1): e80-e90. doi: 10.1097/CCM.0000000000004738
    [13] 景丽丽, 张玉伟, 刘彬, 等. 血清HMGB1、HBP、IL-10水平预测脓毒症预后的临床价值[J]. 中华医院感染学杂志, 2023, 33(1): 31-34.

    JING L L, ZHANG Y W, LIU B, et al. Clinical value of serum HMGB1, HBP and IL-10 in prediction of prognosis of patients with sepsis[J]. Chinese Journal of Nosocomiology, 2023, 33(1): 31-34.
    [14] FISHER J, KAHN F, WIEBE E, et al. The dynamics of circulating heparin-binding protein: implications for its use as a biomarker[J]. J Innate Immun, 2022, 14(5): 447-460. doi: 10.1159/000521064
    [15] 李璐, 吴优, 史娟娟. 血清PTX3、HBP、PGRN水平与产褥期细菌感染所致脓毒症的关联性分析[J]. 淮海医药, 2023, 41(4): 352-355.

    LI L, WU Y, SHI J J, et al. Expression of PTX 3, HBP and PGRN in patients with sepsis induced by puerperal bacterial infection and its clinical significance[J]. Journal of Huaihai Medicine, 2023, 41(4): 352-355.
    [16] KATSAROS K, RENIERIS G, SAFARIKA A, et al. Heparin binding protein for the early diagnosis and prognosis of sepsis in the emergency department: the prompt multicenter study[J]. Shock, 2022, 57(4): 518-525. doi: 10.1097/SHK.0000000000001900
    [17] 高怡宁, 李明晖. 血清标志物在细菌及病毒性脓毒症鉴别诊断中的价值[J]. 浙江医学, 2022, 44(1): 21-24.

    GAO Y N, LI M H. Value of serum markers in differential diagnosis of bacterial and viral sepsis[J]. Zhejiang Medical Journal, 2022, 44(1): 21-24.
    [18] SCHMIDT-ARRAS D, ROSE-JOHN S. Endosomes as signaling platforms for IL-6 family cytokine receptors[J]. Front Cell Dev Biol, 2021, 9: 688314. DOI: 10.3389/fcell.2021.688314.
    [19] 牛凯旋, 吴淑璐, 刘成, 等. 血清淀粉样蛋白A和白细胞介素-6对脓毒症诊断及病情严重程度评估的临床价值[J]. 中华全科医学, 2022, 20(9): 1484-1487. doi: 10.16766/j.cnki.issn.1674-4152.002629

    NIU K X, WU S L, LIU C, et al. Clinical value of serum amyloid A and interleukin-6 in the diagnosis and severity evaluation of sepsis[J]. Chinese Journal of General Practice, 2022, 20(9): 1484-1487. doi: 10.16766/j.cnki.issn.1674-4152.002629
    [20] HIRANO T. IL-6 in inflammation, autoimmunity and cancer[J]. Int Immunol, 2021, 33(3): 127-148. doi: 10.1093/intimm/dxaa078
    [21] 段莉莉, 段榆琳, 刘艳. 脓毒症患者白细胞计数、血清C反应蛋白、肝素结合蛋白、降钙素原表达及与病情进展及预后关系[J]. 临床和实验医学杂志, 2024, 23(6): 589-592.

    DUAN L L, DUAN Y L, LIU Y, et al. Expression of white blood cell count, serum C-reactive protein, heparin binding protein, and procalcitonin in sepsis patients and their relationship with disease progression and prognosis[J]. Journal of Clinical and Experimental Medicine, 2024, 23(6): 589-592.
  • 加载中
图(1) / 表(5)
计量
  • 文章访问数:  7
  • HTML全文浏览量:  4
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2024-12-29
  • 网络出版日期:  2025-10-25

目录

    /

    返回文章
    返回